Quick Answer
PALISADE BIO, INC. reported Operating Income Loss of -$18.06 million for the year ending 2025.
- PALISADE BIO, INC. showed a decrease of -21.5% in Operating Income Loss from 2024 to 2025.
- This data is from PALISADE BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: -$2.89 million | Q2 2013: -$3.24 million | Q3 2013: -$3.63 million | Q4 2013: -$2.76 million | Q1 2014: -$5.18 million | Q2 2014: -$3.51 million | Q3 2014: -$4.11 million | Q4 2014: -$4.64 million | Q1 2015: -$4.61 million | Q2 2015: -$4.99 million | Q3 2015: -$5.20 million | Q4 2015: -$4.35 million | Q1 2016: -$6.23 million | Q2 2016: -$3.83 million | Q3 2016: -$4.92 million | Q1 2017: -$4.23 million | Q2 2017: -$4.22 million | Q3 2017: -$2.59 million | Q1 2018: -$2.35 million | Q2 2018: -$2.02 million | Q3 2018: -$2.08 million | Q1 2019: -$2.46 million | Q2 2019: -$1.92 million | Q3 2019: -$2.12 million | Q1 2020: -$1.99 million | Q2 2020: -$1.84 million | Q3 2020: -$1.82 million | Q1 2021: -$1.95 million | Q2 2021: -$32.86 million | Q3 2021: -$3.02 million | Q1 2022: -$3.89 million | Q2 2022: -$3.57 million | Q3 2022: -$4.41 million | Q1 2023: -$2.53 million | Q2 2023: -$3.61 million | Q3 2023: -$3.78 million | Q1 2024: -$3.67 million | Q2 2024: -$4.21 million | Q3 2024: -$3.59 million | Q1 2025: -$2.31 million | Q2 2025: -$2.84 million | Q3 2025: -$2.92 million.
- Over the full 17 years of available data (2009 to 2025), PALISADE BIO, INC.'s Operating Income Loss has declined by 72.5%.
- Historical annual values: Fiscal year 2025: -$18.06 million | Fiscal year 2024: -$14.86 million | Fiscal year 2023: -$13.07 million | Fiscal year 2022: -$15.72 million | Fiscal year 2021: -$41.85 million | Fiscal year 2020: -$9.30 million | Fiscal year 2019: -$8.63 million | Fiscal year 2018: -$8.26 million | Fiscal year 2017: -$13.31 million | Fiscal year 2016: -$20.64 million | Fiscal year 2015: -$19.16 million | Fiscal year 2014: -$17.44 million | Fiscal year 2013: -$12.52 million | Fiscal year 2012: -$10.16 million | Fiscal year 2011: -$12.99 million | Fiscal year 2010: -$15.18 million | Fiscal year 2009: -$10.47 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: